High Expression of COL17A1 Predicts Poor Prognosis and Promotes the Tumor Progression via NF-κB Pathway in Pancreatic Adenocarcinoma

Feiyu Mao,1 Duguang Li,2 Zechang Xin,3 Yan Du,3 Xiaodong Wang,4 Peng Xu,4 Zhennan Li,4 Jianjun Qian,4 and Jie Yao1,4

1Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, China
2Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
3The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044, China
4Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People’s Hospital, Nantong Western Road, Guangling Qu, Yangzhou, Jiangsu 225001, China

Correspondence should be addressed to Jie Yao; docyao@hotmail.com

Received 25 August 2020; Revised 23 November 2020; Accepted 5 December 2020; Published 16 December 2020

1. Introduction

Pancreatic adenocarcinoma is known for its late-stage diagnosis, aggressive growth, and poor clinical benefit in terms of treatment strategies [1, 2]. At the same time, a patients’ one-year survival rate is 19–34% for all stages of the disease and 4–11% at 5 years because of the high metastatic and recurrent potential [3, 4]. Clinicopathologic parameters, like the TNM system, pathologic classification, and CA19-9 level, have been widely used for prognostic evaluation, but most of them do not fully predict individual clinical outcomes [5, 6]. Until now, researchers have discovered about 12 signaling pathways, abnormal multioncogene activation, or abnormal tumor suppressor gene inactivation that play a part in the growth and acceleration of pancreatic adenocarcinoma [7, 8]. Therefore, to find potential molecular markers and therapeutic targets, unveiling potential molecular mechanism of pancreatic adenocarcinoma has important clinical significance for improving the diagnosis and treatment of the disease.

Upregulated extracellular matrix proteins, like collagens, can promote the first steps of tumor cell metastasis, which
involves invasion into the surrounding tissue and infiltration into the bloodstream in the tumor microenvironment [9]. COL17 (collagen XVII), a transmembrane protein, which is nonfibril forming, is encoded by COL17A1 and is also referred to by the names BP180, ERED, and BPA-2 [10]. COL17A1 is a vital component of mature type I HDs (hemidesmosomes) located in a region at 10q25.1 and has dual roles, as a molecule that adheres to the cell-matrix and a surface receptor for the cell [10]. Furthermore, type-1 HDs disassembly in pancreatic adenocarcinoma has been shown to be associated with COL17 cleavage and may promote pancreatic cancer cell migration and invasion [11]. The onset of autoimmunity to COL17 and COL17A1 mutations cause the epidermis and the membrane beneath it to lose adhesion, thereby leading to blister formation and skin diseases [12,13]. Mutations in COL17A1 may be the leading cause of both generalized atrophic benign and junctional epidermolysis bullosa [14]. COL17 has two homotrimeric forms: a transmembrane protein of full-length and another soluble form called ectodomain, or LAD-1, which is the proteolytically processed full-length form [15,16]. Several studies have documented that type I hemidesmosomes that occur in regular epithelial cells were untraceable in breast cancer cells [17] and pancreatic ductal epithelium [18]. COL17 also expresses highly in normal epithelial tissues, like in the skin, mammary gland, skin, and colon [19]. In epigenetic studies, methylation of COL17A1 promoter can be used to predict its misexpression, patient outcome, and increased invasion in epithelial cancers [9]. Another study has reported a strong correlation between the progression of the tumor and metastasis with enhanced COL17 expression, which was associated significantly with infiltrative growth, distant metastasis, and poor outcome in colorectal carcinoma [20]. A recent report suggests that COL17A1 is a p53 transcriptional target gene and inhibits the metastasis and invasion of breast cancer [21]. However, the expression and biological significance of COL17A1 in pancreatic adenocarcinoma has not been reported yet.

Therefore, we analyzed the expression level of COL17A1 in PDAC tissues. Furthermore, we explored the correlation between COL17A1 expression and clinicopathological characteristics in pancreatic cancer and observed that the overexpression of COL17A1 in pancreatic adenocarcinoma patients is significantly correlated with overall survival (OS). We also found that COL17A1 may promote the proliferative and invasive phenotype of PDAC cells by inactivating the NF-κB (nuclear factor-kappa B) pathway.

2. Materials and Methods

2.1. Patients and Tissue Specimens. All the tissues of pancreatic adenocarcinoma were obtained from the patients who had surgical abscission treatment from October 2015 to October 2019 in Northern Jiangsu People’s Hospital. The aforementioned patients had not undergone chemotherapy or radiation therapy prior to the surgical procedure and were diagnosed independently by two pathologists. One sixty-nine cancerous and 67 noncancerous paraffin-embedded specimens were used for immunohistochemistry. The Cancer Genome Atlas (TCGA) confirmed the differential expression of COL17A1 as well as the Gene Expression Omnibus (GEO) database (GSE62452, GSE28735, GSE15471, GSE62165). The written consent of all the patients was obtained and the study was approved by the Northern Jiangsu People’s Hospital Ethics Committee.

2.2. Immunohistochemistry. The sample was blocked and incubated with the COL17A1 Ab (1:100) for 2 hours at 22°C, and an HRP conjugated goat anti-rabbit Ab was used as the secondary antibody. Two pathologists, blinded for patients’ clinical data independently evaluated the immunohistochemical staining. COL17A1 expression levels were classified by the semiquantitative method that combines the intensity of the staining as well as the percentage of cells that stained positive. The percentage of positive PDAC cells was graded on the following five levels of scores: none: 0; 1–25%; 1; 26–50%; 2; 51–75%; 3; and 76–100%; 4. The staining intensity was graded on the following four levels of the scores as follows: none: 0; weak: 1; moderate: 2; and strong: 3. The low- or high-expression group was decided by the total score which was determined by the percent of positive cell score x staining intensity score (total score > 6: high expression, score ≤ 6: low expression) [18,22].

2.3. Cell Lines and Their Transfection. Shanghai Institute of Nutrition and Health in Shanghai, China, provided the human PDAC cell lines PANC-1, SW1990, AsPC-1, and HPAF-II. The cells were cultured in a medium with streptomycin-penicillin (1%) along with fetal bovine serum (10%) and incubated at a temperature of 37°C and 5% carbon dioxide-fed humidified incubator. As per the manufacturer’s directions, Lipofectamine (Invitrogen, USA) was used for transfection. COL17A1-siRNA (small interfering RNAs) and negative control were synthesized by GenePharma Technology (Shanghai, China), and the overexpressing plasmids COL17A1 were purchased from Hanyin Biotechnology (Shanghai, China).

2.4. Real-Time Quantitative PCR. The Trizol reagent from Invitrogen (China) was used to extract the total RNA while the RT-PCR Kit sourced from Vazyme (China) was used to reverse transcribe the samples. The primers used in this study were COL17A1: forward: 5'-GAGAGCTGATAGTCGCA-3'; reverse: 5'-AATCGAGACCCCTCGCAGCAA-3'; C3H6O3 (Glyceraldehyde)-3-G6PD_N (phosphate dehydrogenase): forward: 5'-GAAGGGTAAAGCTGAGCTCG-3'; reverse: 5'-GAAATGTGGTGATGGGATTTC-3'. Each Ct value was normalized to GAPDH Ct to determine relative expressions. RT-qPCRs were performed according to the MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines [23].

2.5. Western Blot Assay. RIPA buffer (Solarbio, China), containing protease inhibitor was used to lyse the cells and was maintained on ice for 30 min. After transferring the resolved protein from the polyacrylamide gel onto a membrane, 5% mixture of bovine serum albumin from...
Invitrogen (China) was used to block the membranes and incubation was done overnight at 4°C. Subsequently, for a duration of 1 h, incubation was conducted using horseradish peroxidase (HRP) conjugated goat anti-mouse or goat anti-rabbit antibody sourced from Cell Signaling Technology, China. Anti-p-p65, anti-p-IκBα, anti-COL17A1, IκBα, and anti-p65 antibodies sourced from Cell Signaling Technology were used to perform western blot assay and anti-GAPDH antibody (Abcam) was the loading control. Image J was used for calculating the protein expression.

2.6. Transwell and CCK-8 Assays. The incubation was conducted at 24, 48, and 72 h at 37°C. Plates (96-well) were seeded at 5000 cells/well, and then after incubating at 37°C for 2 h, 10 μL from CCK-8 from Synthgene (China) was added. For all of the 24-well plates, pre-diluted Matrigel-coated transwell inserts were used and allowed to gel at 37°C for 30 min. Seeding of the cells was done at a density of 3 × 105 per insert and 500 μL DMEM with 10% fetal bovine serum was mixed to transwell’s lower chamber.
2.7. Detection of Apoptosis and Cell Cycle. Cells (5 × 10^5) were harvested and placed in ice-cold ethanol (70%) for 12 to 24 h. Ribonuclease sourced from Thermo Fisher Scientific at a dosage of 10 mg/ml was added followed by 50 mg/ml of propidium iodide from Sigma and was incubated for 30 min in the dark at 37°C. Flow Cytometry from BD Bioscience (California) was used to analyze the cell cycle. FITC Annexin apoptosis kit from Vazyme (China) was used to analyze apoptosis by incubating the harvested treated cells with these reagents as per the manufacturer’s protocol.

2.8. Tumorigenesis in Nude Mice. Four-to-six-week-old male nude mice (18–20 g) were obtained from the SLAC Laboratory Animal Co., Ltd. (Shanghai, China), and xenograft tumors were generated by using subcutaneous injections of 4 × 10^6 cells. The mice were randomly categorized into the si-COL17A1 subcutaneous injection group and a control group with weekly twice injections. AsPC-1 cells were transduced with lentivirus vectors expressing COL17A1 siRNA. The nude mice were kept in pathogen-free specific conditions. In the course of experimentation on animals, the guidelines of China Animal Welfare Legislation strictly adhered at all times.

2.9. Statistical Analysis. Statistical analyses were carried out using the GraphPad Prism8 software and the SPSS Version 19.0. For real-time PCR, 2-ΔΔCt was calculated, and the inferential statistic Student’s t-test was conducted to determine the p-value among the two groups. A p-value < 0.05 was considered as statistically significant.

3. Results

3.1. COL17A1 Is Upregulated Significantly in Pancreatic Adenocarcinoma. Four microarray datasets from GEO (GSE62452, GSE28735, GSE15471, and GSE62165), TCGA, and GTEx database were analyzed to compute the differential expression of COL17A1 in human PDAC tissue [24–29]. The mRNA levels of expression of COL17A1 were upregulated in the tumor tissues when compared with the normal pancreatic tissue (Figures 1(a) and 1(b)). This is in accordance with the results of public database analysis, and immunohistochemical results show that the COL17A1 protein level was enhanced in tumor tissues in comparison with adjacent normal tissues (Figure 1(c)) at a significant level (p < 0.0001) (Figure 1(d)). These results clearly indicate that in PDAC tissues there was a noticeable increase in COL17A1, the mRNA as well as its protein levels. Further, the level of expression of COL17A1 was estimated in seven PDAC cell lines to select the suitable cells for further experiments (Figure 1(e)) and the siRNA with the best knockdown effect from siRNA1, 2, and 3 was chosen according to RT-qPCR (Figure 1(f)).

3.2. COL17A1 Is Significantly Associated with Lymph Node Metastasis, TNM Clinical Stage, and Pathology Differentiation in PDAC Patients. We used immunohistochemistry to assess the expression of COL17A1 protein in 169 paraffin-embedded pancreatic adenocarcinomas and 67 adjacent normal specimens. The immunostaining for COL17A1 was observed in the cytoplasm of PDAC cells, and 62.7% (106/169) of PDAC samples displayed high expression of COL17A1, while the other 37.3% (63/169) of samples showed low expression (Table 1). χ^2 test showed significant differential expression between PDAC and adjacent normal tissues (Figure 1(f)). Then, the relationship between COL17A1 protein level and the clinicopathologic parameters was analyzed. Table 2 shows the correlation between the COL17A1 and clinicopathologic characteristics; the upregulation of COL17A1 was significantly associated with lymph node metastasis (N0 vs. N1-2; p < 0.0001), TNM clinical stage (I or II vs. III or IV; p < 0.0001) pathology differentiation (high or middle vs. low or no; p < 0.01). However, a negative relationship was found between the expression of COL17A1 and the other

| Table 1: Clinicopathologic characteristics of 169 PDAC patients. |
|-----------------------------|----------------------|
| Patients characteristics    | Number of cases (%)  |
| Age (years)                |                      |
| <60                        | 76 (45.0)            |
| >60                        | 93 (55.0)            |
| Gender                     |                      |
| Male                       | 96 (56.8)            |
| Female                     | 73 (43.2)            |
| Clinical stage             |                      |
| I or II                    | 95 (56.2)            |
| III or IV                  | 74 (43.8)            |
| T classification           |                      |
| T1 or T2                   | 38 (22.5)            |
| T3 or T4                   | 131 (77.5)           |
| N classification           |                      |
| N0                         | 98 (58.0)            |
| N1-2                       | 71 (42.0)            |
| Metastasis                 |                      |
| No                         | 163 (96.4)           |
| Yes                        | 6 (3.6)              |
| Pathologic differentiation |                      |
| High (middle or high)      | 115 (68.0)           |
| Low (No or low)            | 54 (32.0)            |
| Vascular invasion          |                      |
| No                         | 119 (70.4)           |
| Yes                        | 50 (29.6)            |
| Neural invasion            |                      |
| No                         | 87 (51.5)            |
| Yes                        | 82 (48.5)            |
| Vital states (at follow-up)|                      |
| Alive                      | 70 (41.4)            |
| Dead                       | 99 (58.6)            |
| Expression of COL17A1      |                      |
| Low expression             | 63 (37.3)            |
| High expression            | 106 (62.7)           |
Table 2: Interrelationship between expression of COL17A1 and clinicopathologic traits of pancreatic cancer subjects.

| Characteristics          | COL17A1 expression | p value |
|--------------------------|--------------------|---------|
|                          | Low or none       | High    |         |
| Age ≤ 60                 | 30                 | 46      | 0.633   |
| Age > 60                 | 33                 | 60      |         |
| Sex                      | Male               | Female  | 0.749   |
|                          | 37                 | 59      |         |
|                          | 26                 | 47      |         |
| T classification         | T1 or T2           | T3 or T4| 0.182   |
|                          | 18                 | 20      |         |
|                          | 45                 | 86      |         |
| N classification         | N0                 | N1-2    | <0.0001 |
|                          | 56                 | 42      |         |
|                          | 7                  | 64      |         |
| Metastasis               | No                 | Yes     | 0.135   |
|                          | 63                 | 100     |         |
|                          | 0                  | 6       |         |
| Clinical stage           | I or II            | III or IV| <0.0001 |
|                          | 56                 | 39      |         |
|                          | 7                  | 67      |         |
| Pathology differentiation| High (middle or high) | Low (no or low)| <0.01 |
|                          | 53                 | 62      |         |
|                          | 10                 | 44      |         |
| Vascular invasion        | No                 | Yes     | 0.226   |
|                          | 48                 | 71      |         |
|                          | 15                 | 35      |         |
| Neural invasion          | No                 | Yes     | 0.082   |
|                          | 38                 | 49      |         |
|                          | 25                 | 57      |         |

Patients were staged in accordance with the 8th Edition of the AJCC Cancer’s TNM Classification. The numbers in bold indicate that the p values are significant (p < 0.05, the chi-square test).

Figure 2: COL17A1 is significantly correlated with over survival in PDAC patients. (a, b) The Kaplan–Meier survival curves indicate that patients with high expression have a better overall survival time, respectively, from the TCGA database (N = 178, p < 0.01) and our 169 PDAC patients (p < 0.001).
Table 3: Univariate and multivariate Cox regression analyses of prognostic characteristics for overall survival in PDAC patients.

| Prognostic characteristics | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|----------------------|
|                            | p       | HR    | 95% CI     | p       | HR    | 95% CI     |
| Age                        | <0.05   | 1.517 | 1.008–2.282| <0.05   | 1.523 | 1.003–2.313|
| Gender                     | 0.128   | 1.370 | 0.913–2.056| —       | —     | —          |
| Clinical stage             | <0.05   | 1.582 | 1.063–2.354| 0.499   | —     | —          |
| T classification           | <0.01   | 2.281 | 1.327–3.921| 0.081   | —     | —          |
| N classification           | 0.068   | 1.448 | 0.973–2.156| 0.444   | —     | —          |
| Metastasis                 | <0.01   | 4.546 | 1.905–10.845| <0.05   | 2.477 | 1.014–6.053|
| Pathologic differentiation | 0.916   | 1.023 | 0.666–1.573| 0.626   | —     | —          |
| Vascular invasion          | 0.077   | 1.504 | 0.957–2.364| —       | —     | —          |
| Neural invasion            | <0.001  | 2.252 | 1.492–3.400| <0.01   | 1.936 | 1.264–2.966|
| COL17A1                    | <0.01   | 2.201 | 1.394–3.475| <0.01   | 1.885 | 1.177–3.019|

HR: hazard ratio; CI: confidence interval. The numbers in bold indicate that the p values are significant (p < 0.05, Cox regression method: forward LR).

Figure 3: Downregulation of COL17A1 inhibited proliferation and invasion in PDAC cells. The verification of si-COL17A1 downregulation was evaluated by RT-qPCR (a) and western blotting in AsPC-1 and HPAF-II cells (b, c). Effects of COL17A1 downregulation on proliferation and migration were done by wound healing (d)-(e) and CCK-8 (f, g) assays. (h, i) Transwell assay measured the COL17A1 downregulation effects on the invasion. Results shown are the mean ± SD (* p < 0.05, ** p < 0.01, and *** p < 0.001; the experiments were repeated at least three times). siRNA: transfected with small interfering RNAs.
3. Clinicopathologic factors, such as T classification, distant metastasis, gender, age, vascular invasion, and neural invasion.

3.3. Upregulated COL17A1 Predicts Poor Prognosis in PDAC Patients. We analyzed the relationship between COL17A1 expression and the OS time to evaluate the prognostic value of COL17A1 in PDAC according to the Kaplan–Meier survival curves and the log-rank test. Patients with high COL17A1 expression all had a significantly lesser OS than those with low expression in 178 (TCGA) and 169 (our cohort) PDAC patients (p < 0.01 and p < 0.001 resp., log-rank test) (Figures 2(a) and 2(b)).
In addition, we validated that COL17A1 features as an independent risk factor for patients' prognosis by univariate and multivariate analyses. Univariate Cox regression analysis indicated that age, clinical stage, T classification, metastasis, neural invasion, and the expression of COL17A1 were significantly associated with prognostic significance. In the multivariate Cox regression analysis, age, metastasis, neural invasion, and the expression of COL17A1 were independent prognostic predictors (Table 3) \( (p < 0.05, \ p < 0.01, \text{ and } \ p < 0.001). \) These findings showed that upregulated COL17A1 may be an independent prognosis factor in PDAC patients.

### 3.4. COL17A1 Promotes the Proliferation and Invasion of PDAC Cells In Vitro

To test if COL17A1 promoted PDAC cell proliferation and invasion, we knocked down the expression of COL17A1 in AsPC-1 and HPAF-II cells with siRNA-COL17A1 and overexpressed COL17A1 in PANC-1, and SW1990 cells. The transfection efficiency was confirmed by RT-qPCR and western blot (Figures 3(a)–3(c) and Figures 4(a)–4(c)). Then, wound healing, CCK-8 assays, and transwell assays showed that the knockdown of COL17A1 notably inhibited the proliferation and invasion of AsPC-1 and HPAF-II cells compared to those in the control (Figures 3(d)–3(i)). While cells with COL17A1 overexpression had a prominently higher proliferative and invasive capacity than negative control in PANC-1 and SW1990 cells (Figures 4(d)–4(i)), these findings suggest that COL17A1 can enhance the proliferative and invasive ability of pancreatic adenocarcinoma cells.

### 3.5. COL17A1 May Promote PDAC Progression by Inactivating Cell Apoptosis

Cell apoptosis assay results show that knockdown of COL17A1 significantly upregulated the apoptosis level of AsPC-1 and HPAF-II cells compared with those in the control (Figures 5(a) and 5(b)). Further, COL17A1 overexpression cells had prominently lower apoptosis than negative control PANC-1 and SW1990 cells (Figures 5(c) and 5(d)). Therefore, COL17A1 may promote PDAC progression by inactivating cell apoptosis.

### 3.6. COL17A1 Promotes PDAC Progression by Activating NF-Kappa B Signaling Pathway

To further elucidate the role of COL17A1 in signaling pathways, western blotting assays were performed to examine the expression of p65, phospho-p65, p65 (cytoplasm), p65 (nuclear), IκBα, and phospho-IκB-α. We found that phospho-p65 and phospho-IκB-α were noticeably enhanced in cells that were overexpressing COL17A1 but decreased in si-COL17A1 cells. p65 in the nucleus was significantly increased in COL17A1-overexpressing cells but decreased in si-COL17A1 cells (Figures 6(a)–6(c)). These results, thus, showed that COL17A1 may promote the NF-κB signaling pathway activation in apoptosis.

### 3.7. COL17A1 Promotes Tumor Growth In Vivo

To determine the effects of COL17A1 in vivo, AsPC-1 cells were subcutaneously injected into the flanks of nude mice in two groups: the AsPC-1 cells with stable knockdown of COL17A1 gene were injected in the experimental group, and normal AsPC-1 cells were injected in the control group. The tumor growth rates in mice injected with siRNAs-COL17A1 cells were slower than in the control mice (Figures 7(a)–7(d)). Therefore, our data suggest that COL17A1 has a positive effect on the in vivo growth of PDAC cells.
4. Discussion

The joint diagnosis of the imaging evaluations and molecular biomarkers cannot entirely monitor the occurrence, progression, and early metastasis of PDAC, so new noninvasive diagnosis strategies are urgently needed. Our data show that the expression of COL17A1 is very high in pancreatic cancer tissues and is closely related to the patients’ overall survival time. Stepwise analyses indicate that COL17A1 is an independent prognostic factor for PDAC. However, COL17A1 expression was not significantly correlated with any clinicopathologic factors except the pathology differentiation. The reason for this finding may be limited sample size, in addition to the current treatment strategy and the short overall survival of patients with PDAC. Our results further showed that COL17A1 may promote cell multiplication and attack and inhibit cell apoptosis in PDAC by activating the NF-κB pathway. Collectively, our data suggest that COL17A1 may be a unique biomarker for clinical diagnosis, prognostic assessment, and the therapy of PDAC patients.

Some studies have shown upregulated COL17A1 in ductal breast cancers, prostate carcinoma, cutaneous
squamous cell, and basal cell carcinomas [9] and in cervical cancer and squamous cell carcinomas [30–34]. Our results indicate that COL17A1 assumes an oncogene role in many cancers. It is well known that the initial stage of the progression of epithelial cancer characterizes the failure in adhesion of cells and the persistent biological function of related adhesion proteins [35], and this may be related to the type I hemidesmosomes (HDs), which is composed of COL17. Our results further show that the increased expression of COL17A1 in PDAC had a positive correlation with increased cell invasion and progression. A recent study showed that a novel PTEN-COL17A1 fusion gene is involved in regulating COL17 expression and glioblastoma multiforme (GBM) aggressiveness and determined that COL17A1 may play the roles of a prognostic biomarker and potential therapeutic targets of GBM [36]. We, therefore, speculate that COL17A1 works through cell surface receptors to mediate tumor progression as against the function of cell-matrix adhesion molecules in PDAC. COL17A1 and other three adhesion molecules (BPAG1, CDHF7, and CD97) show downregulation mainly between the premalignant and stage II cells and between the normal myoepithelial and the premalignant cells in breast cancer [37]; therefore, we guess that the stage-specificity of COL17A1 may exist in pancreatic cancer because of limited samples even if our results did not show a significant association between COL17A1 expression and clinical stage.

Cells can activate the apoptosis inhibition pathway by targeting the proapoptosis factors and upregulating the antiapoptosis factors expressions to maintain cell survival [38]. NF-κB plays key and complex roles in cell apoptosis; some studies show that TNF-α plays a dual role in apoptosis, those of promoting apoptosis by activating caspase-8 and -10 or suppressing apoptosis by activating NF-κB [39, 40]. IAP (inhibitors of apoptosis) can help the cancer cells survival and proliferation by stimulating their biological activity [41]. The IAP may promote cell survival and tumorigenesis according to the ability of many IAPs to function as ubiquitin-E3 ligases which can regulate NF-κB signaling [42]. The activation of this kind of noncanonical NF-κB signaling also frequently takes place in pancreatic cancers [43]. Gemcitabine in combination with p65 siRNA can control the proliferation of pancreatic cancer cells and induce apoptosis as well, both in vivo and in vitro, and curtail the growth and angiogenesis of tumors in nude mice, and this can be a welcome solution as pancreatic cancer treatment is an important issue all over the world [44]. Recently, studies reported that isodeoxyelephantopin (IDET) may function as an anticarcinogenic via the NF-κB inactivation and the regulation of oncogenic lncRNA expression in breast cancer [45]. In addition, NF-κB may present a unique target for tumor avoidance and therapy in combination with inhibition of transcription factors, such as Stat3 [46]. Our data also indicate that COL17A1 may mediate the inhibition of...
pancreatic cancer cells apoptosis by activating the NF-κB signaling pathway.

In summary, our study revealed that overexpression of COL17A1 is related to reduced survival in PDAC subjects, and COL17A1 can promote proliferative abilities and invasiveness in PDAC putatively suppress apoptosis via the NF-κB pathway. Additionally, COL17A1 may serve as a potential molecular therapeutic target. However, our study has some limitations, like limited samples, validation of therapeutic target, and the need for more detailed mechanisms to hence lay the foundation for further research.

Data Availability
The data about clinicopathologic characteristics of 169 PDAC patients used to support the findings of this study are available from the corresponding author upon request (e-mail: docyao@hotmail.com).

Ethical Approval
All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments. In the course of experimentation on animals, adherence to the guidelines of China Animal Welfare Legislation was kept at all times.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
FM, DL, and JY conceived and designed this study. The clinical tissue specimens were collected by FM, YD, and ZX. The experiments and the data analyses were carried out by FM and DL. Other authors including NL, XW, JQ, and PX also participated in the data analyses of this study. The manuscript was written by FM and DL and supervised by JY. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work was appropriately investigated and resolved. Feiyu Mao and Duguang Li contributed equally to this work.

Acknowledgments
This study was supported by a grant from the National Natural Science Foundation of China (no. 81772516).

References
[1] M. Hidalgo, S. Cascinu, J. Kleeff et al., “Addressing the challenges of pancreatic cancer: future directions for improving outcomes,” Pancreatology, vol. 15, no. 1, pp. 8–18, 2015.
[2] J. Werner, S. E. Combs, C. Springfeld, W. Hartwig, T. Hackert, and M. W. Büchler, “Advanced-stage pancreatic cancer: therapy options,” Nature Reviews Clinical Oncology, vol. 10, no. 6, pp. 323–333, 2013.
[3] L. Huang, L. Jansen, Y. Balavarca et al., “Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study,” BMC Medicine, vol. 16, p. 125, 2018.
[4] M. Ilic and I. Ilic, “Epidemiology of pancreatic cancer,” World Journal of Gastroenterology, vol. 22, no. 44, pp. 9694–9705, 2016.
[5] G. J. Rieser, M. Zenati, A. Hamad et al., “CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time,” Annals of Surgical Oncology, vol. 25, no. 12, pp. 3483–3491, 2018.
[6] D. Chatterjee, M. H. Katz, W. C. Foo et al., “Prognostic significance of new AJCC tumor stage in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy,” The American Journal of Surgical Pathology, vol. 41, no. 8, pp. 1097–1104, 2017.
[7] T. Kamisawa, L. D. Wood, T. Itoi, and K. Takaori, “Pancreatic cancer,” The Lancet, vol. 388, no. 10039, pp. 73–85, 2016.
[8] S. Jones, X. Zhang, D. W. Parsons et al., “Core signaling pathways in human pancreatic cancers revealed by global genomic analyses,” Science, vol. 321, no. 5897, pp. 1801–1806, 2008.
[9] P. U. Thangavelu, T. Krenacs, E. Dray, and P. H. Duijf, “In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion,” Clin Epigenetics, vol. 8, p. 120, 2016.
[10] A. Seppanen, “Collagen XVII: a shared antigen in neurodermatological interactions?” Clinical and Developmental Immunology, vol. 2013, Article ID 240579, 7 pages, 2013.
[11] S. Laval, H. Laklai, M. Fanjul et al., “Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides,” Oncogene, vol. 33, no. 15, pp. 1934–1944, 2014.
[12] S.-H. Hong, S.-H. Goh, S. J. Lee et al., “Upregulation of adenylate cyclase 3 (ADCY3) increases the tumorigenic potential of cells by activating the CREB pathway,” Oncotarget, vol. 4, no. 10, pp. 1791–1803, 2013.
[13] R. Zuloaga, E. N. Fuentes, A. Molina, and J. A. Valdés, “The cAMP response element binding protein (CREB) is activated by insulin-like growth factor-1 (IGF-1) and regulates myostatin gene expression in skeletal myoblast,” Biochemical and Biophysical Research Communications, vol. 440, no. 2, pp. 258–264, 2013.
[14] M. Floeth, H. Schäcke, N. Hammami-Hauasli et al., “Novel homozygous and compound heterozygous COL17A1 mutations associated with junctional epidermolysis bullosa,” Journal of Investigative Dermatology, vol. 111, no. 3, pp. 528–533, 1998.
[15] F. Van den Bergh, S. L. Eliason, and G. J. Giudice, “Type XVII collagen (BP180) can function as a cell–matrix adhesion molecule via binding to laminin 332,” Matrix Biology, vol. 30, no. 2, pp. 100–108, 2011.
[16] W. Nishie, D. Kiritsi, A. Nystrom, S. C. Hofmann, and L. Bruckner-Tuderman, “Dynamic interactions of epidermal collagen XVII with the extracellular matrix,” The American Journal of Pathology, vol. 179, no. 2, pp. 829–837, 2011.
[17] K. M. Sakamoto and D. A. Frank, “CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy,” Clinical Cancer Research, vol. 15, no. 8, pp. 2583–2587, 2009.
[18] M. Tsuboi, K. Taniuchi, M. Furihata et al., “Vav3 is linked to poor prognosis of pancreatic cancers and promotes the motility and invasiveness of pancreatic cancer cells,” Pancreatology, vol. 16, no. 5, pp. 905–916, 2016.
[19] J. M. Strempel and D. Vercelli, "Functional dissection identifies a conserved noncoding sequence-1 core that mediates IL13 and IL4 transcriptional enhancement," The Journal of Biological Chemistry, vol. 282, no. 6, pp. 3738–3746, 2007.

[20] J. M. Moilanen, N. Kokkonen, S. Loffel et al., "Collagen XVII expression correlates with the invasion and metastasis of colorectal cancer," Human Pathology, vol. 46, no. 3, pp. 434–442, 2015.

[21] V. Yodsurang, C. Tanikawa, T. Miyamoto, P. H. Y. Lo, M. Hirata, and K. Matsuda, "Identification of a novel p53 target, COL17A1, that inhibits breast cancer cell migration and invasion," Oncotarget, vol. 8, no. 34, pp. 55790–55803, 2017.

[22] Y. Miyazawa, T. Uekita, N. Hiraoka et al., "CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation," Cancer Research, vol. 70, no. 12, pp. 5136–5146, 2010.

[23] S. A. Bustin, V. Benes, J. A. Garson et al., "The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments," Clinical Chemistry, vol. 55, no. 4, pp. 611–622, 2009.

[24] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses," Nucleic Acids Research, vol. 45, no. W1, pp. W98–w102, 2017.

[25] T. Idichi, N. Seki, H. Kurahara et al., "Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma," Oncotarget, vol. 8, no. 32, pp. 53180–53193, 2017.

[26] R. Janky, M. M. Binda, J. Allemersch et al., "Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma," BMC Cancer, vol. 16, p. 632, 2016.

[27] G. Zhang, P. He, H. Tan et al., "Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer," Clinical Cancer Research, vol. 19, no. 18, pp. 4983–4993, 2013.

[28] G. Zhang, A. Schetter, P. He et al., "DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma," PLoS One, vol. 7, Article ID e31507, 2012.

[29] S. Yang, P. He, J. Wang et al., "A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2," Cancer Research, vol. 76, no. 13, pp. 3838–3850, 2016.

[30] A. Chopra, B. Maitra, and N. J. Korman, "Decreased mRNA expression of several basement membrane components in basal cell carcinoma," Journal of Investigative Dermatology, vol. 110, no. 1, pp. 52–56, 1998.

[31] V. Dumas, J. Kanitakis, S. Charvat, S. Euvrard, M. Faure, and A. Claudy, "Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas," Anticancer Research, vol. 19, pp. 2929–2938, 1999.

[32] T. Ernst, M. Hergenhahn, M. Kenzelmann et al., "Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma," The American Journal of Pathology, vol. 160, no. 6, pp. 2169–2180, 2002.

[33] J. A. Fairley, P. W. Heintz, M. Neuburg, L. A. Diaz, and G. J. Giudice, "Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia," The British Journal of Dermatology, vol. 133, no. 3, pp. 385–391, 1995.

[34] T. Yamada, R. Endo, K. Tsukagoshi et al., "Aberrant expression of a hemidesmosomal protein, bullous pemphigoid antigen 2, in human squamous cell carcinoma," Laboratory Investigation; a Journal of Technical Methods and Pathology, vol. 75, no. 4, pp. 589–600, 1996.

[35] T. L. Davis, A. J. Goldman, and A. E. Cress, "Suppression and alteration of adhesion structures in human epithelial cancer progression," in Cell Adhesion and Cytoskeletal Molecules in Metastasis, A. E. Cress and R. B. Nagle, Eds., pp. 19–46, Springer, Dordrecht, Netherlands, 2006.

[36] X. Yan, C. Zhang, T. Liang et al., "A PTEN-COL17A1 fusion gene and its novel regulatory role in Collagen XVII expression and GBM malignance," Oncotarget, vol. 8, no. 49, pp. 85794–85803, 2017.

[37] T. Geiger, S. F. Madden, W. M. Gallagher, J. Cox, and M. Mann, "Proteomic portrait of human breast cancer progression identifies novel prognostic markers," Cancer Research, vol. 72, no. 9, pp. 2428–2439, 2012.

[38] G. Brumatti, M. Salamanidis, and P. G. Ekert, "Crossing paths: interactions between the cell death machinery and growth factor survival signals," Cellular and Molecular Life Sciences, vol. 67, no. 10, pp. 1619–1630, 2010.

[39] T. Kaufmann, A. Strasser, and P. J. Jost, "Fas death receptor signalling: roles of Bid and XIAP," Cell Death and Differentiation, vol. 19, no. 1, pp. 42–50, 2012.

[40] Y. Rong and C. W. Distelhorst, "Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis," Annual Review of Physiology, vol. 70, no. 1, pp. 73–91, 2008.

[41] S. Fulda and D. Vucic, "Targeting IAP proteins for therapeutic intervention in cancer," Nature Reviews Drug Discovery, vol. 11, no. 2, pp. 109–124, 2012.

[42] J. Lopez and P. Meier, "To fight or die-inhibitor of apoptosis proteins at the crossroad of innate immunity and death," Current Opinion in Cell Biology, vol. 22, no. 6, pp. 872–881, 2010.

[43] P. Storz, "Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?" Expert Review of Anticancer Therapy, vol. 13, no. 5, pp. 501–504, 2013.

[44] R. Kong, B. Sun, H. Jiang et al., "Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer," Cancer Letters, vol. 291, no. 1, pp. 90–98, 2010.

[45] S. S. Verma, V. Rai, N. Awasheet al., "Iso-deoxyelephantopin, a sesquiterpene lactone induces ROS generation, suppresses NF-kappaB activation, modulates LncRNA expression and exhibit activities against breast cancer," Scientific Report, vol. 9, Article ID 17980, 2019.

[46] F. R. Greten, C. K. Weber, T. F. Greten et al., "Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis," Gastroenterology, vol. 123, no. 6, pp. 2052–2063, 2002.